- Home
- ZLAB
ZLAB
Zai Lab Limited
as 06-13-2025 12:44pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 3.6B | IPO Year: | 2017 |
| Target Price: | $47.37 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.01 - $44.34 | Next Earning Date: | 08-05-2025 |
| Revenue: | $418,326,000 | Revenue Growth: | 43.72% |
| Revenue Growth (this year): | 44.07% | Revenue Growth (next year): | 49.13% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chen Yajing | ZLAB | Chief Financial Officer | Jun 2 '25 | Sell | $30.00 | 9,618 | $288,540.00 | 17,429 | |
| Du Ying | ZLAB | Chairperson & CEO | May 13 '25 | Sell | $28.59 | 96,389 | $2,731,506.99 | 479,851 | |
| Du Ying | ZLAB | Chairperson & CEO | May 9 '25 | Sell | $29.78 | 100,000 | $2,953,307.66 | 479,851 | |
| Morrison Scott W | ZLAB | Director | May 9 '25 | Sell | $30.05 | 23,799 | $715,086.17 | 23,702 | |
| Du Ying | ZLAB | Chairperson & CEO | Apr 3 '25 | Sell | $33.11 | 2,945 | $97,503.06 | 479,851 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Apr 3 '25 | Sell | $33.11 | 924 | $30,591.79 | 17,429 | |
| Smiley Joshua L | ZLAB | See Remarks | Apr 3 '25 | Sell | $33.11 | 3,354 | $111,044.23 | 67,345 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 3 '25 | Sell | $33.11 | 1,874 | $62,044.39 | 30,375 | |
| Amado Rafael | ZLAB | See Remarks | Apr 3 '25 | Sell | $33.11 | 3,029 | $100,284.13 | 45,178 | |
| Du Ying | ZLAB | Chairperson & CEO | Apr 1 '25 | Sell | $35.89 | 5,808 | $208,472.35 | 479,851 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
MT Newswires
5 hours ago
Zai Lab Reports Positive Results From Preclinical Study of ZL-1503 in Atopic Dermatitis
Business Wire
6 hours ago
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
MT Newswires
9 days ago
Zai Lab Insider Sold Shares Worth $288,540, According to a Recent SEC Filing
Business Wire
11 days ago
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Business Wire
13 days ago
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Newsfile
14 days ago
Sienna Resources Inc. Announces Private Placement
Energy Global
14 days ago
European Energy completes sale of Polish wind portfolio to Enea Group
Newsfile
14 days ago
Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.